Antonio J. Carcas

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 386 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe

Alberto M. Borobia, Antonio J. Carcas, Rodolfo Álvarez-Sala et al. · Journal of Clinical Medicine · 2020 · 291 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +10

Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression

José Ramón Arribas, Federico Pulido, Rafaël Delgado et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 149 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

Belén Gutiérrez‐Gutiérrez, Alberto M. Borobia, Antonio J. Carcas et al. · The Lancet Infectious Diseases · 2021 · 102 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +13

Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score

Juan Berenguer, Alberto M Borobia, Pablo Ryan et al. · Thorax · 2021 · 96 citations · Full text

Medicine, Emergency Medicine, Internal Medicine +17